Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Allos Therapeutics |
---|---|
Information provided by: | Allos Therapeutics |
ClinicalTrials.gov Identifier: | NCT00606502 |
The purpose of this clinical study is to determine the effectiveness (ability to provide beneficial treatment of the disease) and safety of paralatrexate compared to erlotinib (Tarceva) when given to NSCLC patients who are current or former cigarette smokers and who have received at least 1 prior treatment with a platinum drug (cisplatin or carboplatin)
Condition | Intervention | Phase |
---|---|---|
Non-Small Cell Lung Cancer |
Drug: Erlotinib Drug: Pralatrexate Injection |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Protocol PDX-012: A Randomized, Phase 2b, Multi-Center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-Based Treatment |
Estimated Enrollment: | 160 |
Study Start Date: | January 2008 |
Estimated Study Completion Date: | July 2011 |
Estimated Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Pralatrexate Injection: Active Comparator |
Drug: Pralatrexate Injection
Patients randomized to the Pralatrexate Arm will receive pralatrexate as an IV push administration over 3-5 minutes via a patent IV line containing normal saline (0.9% sodium chloride [NaCl]) administered on days 1 and 15 of a 4-week/28-day cycle.
|
Erlotinib: Active Comparator |
Drug: Erlotinib
Erlotinib is supplied in 25 mg, 100 mg, and 150 mg dosage strengths as white film-coated tablets for daily oral administration. Patients in the Erlotinib Arm will receive erlotinib 150 mg/day orally 1 hour before or 2 hours after the ingestion of food. Dosing will be continuous.
|
This is a randomized, Phase 2b, clinical study comparing pralatrexate and erlotinib in patients with Stage IIIB/IV NSCLC who are or have been cigarette smokers. Patients will be randomized 1:1 to pralatrexate or erlotinib. Patients randomized to the Pralatrexate Arm will receive pralatrexate as an intravenous (IV) push administration over 3 5 minutes via a patent IV line containing normal saline administered on days 1 and 15 of a 4 week/28 day cycle. The initial dose of pralatrexate will be 230 mg/m2 which, based on defined criteria, may be increased to 270 mg/m2 or reduced in 40 mg/m2 decrements. The lowest dose allowed is 190 mg/m2; if a patient cannot tolerate 190 mg/m2, pralatrexate must be discontinued. Patients randomized to the Erlotinib Arm will receive erlotinib 150 mg/day orally 1 hour before or 2 hours after the ingestion of food. Dosing will be continuous. For the purposes of this study, a cycle will be considered 4 weeks/28 days, to include: day 1 and 15 of pralatrexate or day 1 28 of daily erlotinib administration. All patients will receive vitamin therapy. A patient may begin study treatment provided he/she has been on a regimen of 1 1.25 mg orally (PO) every day (QD) of folic acid for at least 7 days prior to randomization and has received 1 mg intramuscular injection (IM) of vitamin B12 within 10 weeks prior to randomization. Once the patient is randomized, the dosing of vitamin supplementation will consist of vitamin B12 1 mg IM every (q) 8 10 weeks, and folic acid 1 1.25 mg PO QD.
Treatment will continue until development of progressive disease (PD); initiation of radiation therapy (RT) or systemic therapy for NSCLC; more than 4 weeks between doses of pralatrexate or erlotinib; development of an AE that interferes with the patient's participation; patient refuses further treatment or withdraws consent; investigator decision; or sponsor decision. Patients will be followed to determine time to PD, first subsequent treatment for NSCLC, and survival for up to 2 years post-randomization or until 35 (±5) days after the last treatment, whichever is longer.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Active concurrent primary malignancy (except non-melanoma skin cancer or in situ carcinoma of the cervix).
If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years.
Study Chair: | Karen Kelly, MD | University of Kansas |
Responsible Party: | Allos Therapeutics, Inc. ( Medical Monitor ) |
Study ID Numbers: | PDX-012, Grantor: CDER, IND/IDE Number: 52,604, Serial Number: 0177 |
Study First Received: | January 22, 2008 |
Last Updated: | July 8, 2009 |
ClinicalTrials.gov Identifier: | NCT00606502 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Stage IIIB/IV non-small cell lung cancer Non-small cell lung cancer NSCLC Lung Cancer Pralatrexate |
Erlotinib Tarceva PDX Smoking Smoker |
Erlotinib Thoracic Neoplasms Smoking Respiratory Tract Diseases Lung Neoplasms Lung Diseases |
Non-small Cell Lung Cancer Protein Kinase Inhibitors Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Thoracic Neoplasms Erlotinib Respiratory Tract Neoplasms Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |
Carcinoma Neoplasms Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |